In The News Posted July 12, 2019 Share Posted July 12, 2019 STOCKHOLM, July 12, 2019 /PRNewswire/ -- Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its first-in-human, clinical phase I, trial with drug candidate T20K, in development for the treatment... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.